Metastatic Colorectal Cancer
MOUNTAINEER-03 (NCT05253651) is a global, open-label,  randomized, phase 3 study of tucatinib with trastuzumab and  mFOLFOX6 versus standard of care for the first-line treatment of  HER2+ and RAS wild-type mCRC

Released: February 01, 2023

Expiration: January 31, 2024

Tanios Bekaii-Saab
Tanios Bekaii-Saab, MD, FACP

Activity

Progress
1
Course Completed